Research notes: Tips for navigating federal funding from the lab to the internet

houston voices

As a researcher, what is more important to you than a record of your research and scholarship? A Digital Persistent Identifier, or DPI, distinguishes you and your work from that of your peers. Graphic by Miguel Tovar/University of Houston

Every researcher needs a Digital Persistent Identifier.

As a researcher, what is more important to you than a record of your research and scholarship? A Digital Persistent Identifier, or DPI, distinguishes you and your work from that of your peers – and having one will be mandated for those receiving federal funding. Let’s take a deeper look at why this number is so important. We’ll also compare the different platforms— ORCID, Web of Science, Scopus and Google Scholar — so that you can be sure your publications, presentations, peer reviews and even information about who is citing you are being properly stored and accessed.

ORCID

There are many types of profiles and DPIs that can meet your needs, but there’s no silver bullet. Placing your work onto multiple platforms is necessary according to Andrea Malone, Research Visibility and Impact Coordinator at UH Libraries. She cautions researchers to “be realistic about how many identifiers you can maintain.”

The most popular is ORCID, which stands for Open Researcher and Contributor ID. It’s free to set up, and there is no chance of accidentally or on-purpose having multiple ORCID accounts – it’s assigned to you like a social security number and follows you, the researcher. This comes in particularly especially handy for researchers with common names.

An identifier is federally mandated for those receiving governmental funds. It is not specified that ORCID must be that identifier. For example, according to Malone: “a Web of Science profile also assigns an identifier, which would also satisfy the mandate.” But most researchers choose ORCID because it’s publicly available with no access restrictions.

While an ORCID number is free for researchers, there is a subscription fee for an institution to be associated with ORCID. Information will not pre-populate in an ORCID profile and it doesn’t track citation counts – it only shows what you put in. There are, however, linking wizards that allow you to link from Web of Science and Scopus to your ORCID account. If you choose this option, citations will automatically populate in your ORCID profile. It’s up to the researcher to doublecheck to be sure the information has automated, however.

Google Scholar

Google Scholar is a profile, not an identifier, so it does not comply with federal funding requirements. It is free, however, and it pulls from the open web. You can choose to have your list of articles updated automatically, review the updates yourself or manually update your articles at any time. Google Scholar also specifies which articles are open access. A PDF or HTML icon will appear on the righthand side of each citation for one to download articles.

Web of Science Vs. Scopus

Scopus is known for covering more journals and a wider range of metrics to evaluate research impact than Web of Science. Different platforms are a go-to for certain disciplines – for example, Web of Science is usually associated with hard sciences, although investigators in the social sciences and humanities also place their work on this platform from time to time. It’s a good idea to check out which platforms others in your discipline are using for their profiles.

Staying up-to-date

Of course, DPIs don’t work as intended unless researchers keep their profiles current. That means you need to check your profile after every publication and every time you switch to a new institution. Just as you would update your CV, you must update your ORCID or other DPI profile.

One tactic Malone suggests is setting a schedule either biweekly or monthly to check all your profiles. “One thing that’s helpful is that with all of them, you can set up alerts and create an alert as often as you want,” Malone goes on. “At that time, the program will scrawl the content within the source and alert you to anytime any of your publications appear in their database.”

The Big Idea

No one tool can paint a complete picture of all your scholarship. Be strategic and intentional about which platforms you use. Consider your audience, the platforms others in your discipline use and make sure you have an ORCID profile to comply with the federal mandate. But be careful not to sign up for more than you can feasibly maintain and keep current.

------

This article originally appeared on the University of Houston's The Big Idea. Sarah Hill, the author of this piece, is the communications manager for the UH Division of Research.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

View All Listings